epidyolex
chiesi new zealand limited t/a emerge health - cannabidiol 100 mg/ml; ; ; - oral solution - 100 mg/ml - active: cannabidiol 100 mg/ml excipient: ethanol sesame oil strawberry flavour 501094 a sucralose - epidyolex is indicated for use as adjunctive therapy of seizures associated with lennox-gastaut syndrome (lgs) or dravet syndrome (ds) for patients 2 years of age and older.
diacomit
chiesi new zealand limited t/a emerge health - stiripentol 250mg; - capsule - 250 mg - active: stiripentol 250mg excipient: erythrosine gelatin indigo carmine ink black 10a2 magnesium stearate povidone sodium starch glycolate titanium dioxide - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.
diacomit
chiesi new zealand limited t/a emerge health - stiripentol 500mg; - capsule - 500 mg - active: stiripentol 500mg excipient: gelatin ink black 10a2 magnesium stearate povidone sodium starch glycolate titanium dioxide - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.
diacomit
chiesi new zealand limited t/a emerge health - stiripentol 250mg; - powder for oral suspension - 250 mg - active: stiripentol 250mg excipient: aspartame carmellose sodium erythrosine hyetellose spray-dried glucose liquid povidone sodium starch glycolate titanium dioxide tutti frutti flavour 25h245 - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.
diacomit
chiesi new zealand limited t/a emerge health - stiripentol 500mg; - powder for oral suspension - 500 mg - active: stiripentol 500mg excipient: aspartame carmellose sodium erythrosine hyetellose spray-dried glucose liquid povidone sodium starch glycolate titanium dioxide tutti frutti flavour 25h245 - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.
atimos modulite 12micrograms/dose inhaler
chiesi ltd - formoterol fumarate dihydrate - pressurised inhalation - 12microgram/1dose
fostair 200micrograms/dose / 6micrograms/dose inhaler
chiesi ltd - beclometasone dipropionate; formoterol fumarate dihydrate - pressurised inhalation - 200microgram ; 6microgram
fostair 100micrograms/dose / 6micrograms/dose inhaler
chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram/1dose ; 100microgram/1dose
bramitob 300mg/4ml nebuliser solution 4ml ampoules
chiesi ltd - tobramycin - nebuliser liquid - 75mg/1ml
curosurf 240mg/3ml endotracheopulmonary suspension vials
chiesi ltd - poractant alfa - suspension for endotracheopulmonary instillation - 80mg/1ml